Novo Nordisk, a leading pharmaceutical company, announced on Monday the positive outcomes of a late-stage study evaluating the oral version of their drug semaglutide, known as Rybelsus. The study demonstrated that Rybelsus significantly lowered the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease. In a cohort of 9,650 participants, Rybelsus reduced the risk of cardiovascular death, non-fatal heart attacks, and strokes by 14% when compared to a placebo, achieving the primary objective of the trial.
The results suggest that Rybelsus could potentially be a valuable addition to the standard of care for individuals with these conditions. Novo Nordisk plans to seek regulatory approval for a label expansion of Rybelsus in both the United States and the European Union in the coming months. In addition, the company intends to present more detailed findings from the study at an upcoming scientific conference scheduled for next year.
These findings represent a significant advancement in the treatment of patients at high risk for cardiovascular events and underline the potential of Rybelsus as a beneficial therapeutic option. The successful outcomes of this trial could pave the way for improved management of cardiovascular risk in individuals with type 2 diabetes and comorbid conditions, offering hope for better health outcomes in the future.